A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib

Ann Oncol. 2015 Jan;26(1):246-248. doi: 10.1093/annonc/mdu471. Epub 2014 Oct 20.

Authors

M Rechsteiner¹, P Wild¹, M K Kiessling², A Bohnert¹, Q Zhong¹, R A Stahel², H Moch¹, A Curioni-Fontecedro³

Affiliations

¹ Institute of Surgical Pathology.
² Department of Oncology, University Hospital Zurich, Zurich, Switzerland.
³ Department of Oncology, University Hospital Zurich, Zurich, Switzerland. Electronic address: [email protected].

PMID: 25336117
DOI: 10.1093/annonc/mdu471

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics
Adult
Antineoplastic Agents / therapeutic use*
Bone Neoplasms / drug therapy
Bone Neoplasms / secondary
Germ-Line Mutation
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / secondary
Male
Phenylurea Compounds / therapeutic use*
Pyridines / therapeutic use*
Receptor, Platelet-Derived Growth Factor beta / genetics*
Rectal Neoplasms / drug therapy*
Rectal Neoplasms / genetics
Treatment Outcome

Substances

Antineoplastic Agents
Phenylurea Compounds
Pyridines
regorafenib
Receptor, Platelet-Derived Growth Factor beta